Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic acid
M Lechowicz, DP Dittmer, JY Lee… - Clinical infectious …, 2009 - academic.oup.com
M Lechowicz, DP Dittmer, JY Lee, SE Krown, W Wachsman, D Aboulafia, BJ Dezube…
Clinical infectious diseases, 2009•academic.oup.comAbstract The AIDS Malignancy Consortium undertook a pilot trial of valproic acid among
patients with AIDS-associated Kaposi sarcoma (KS). Treatment was associated with low
toxicity, but the KS clinical response and KS herpesvirus lytic induction rates were not
sufficiently high to meet predefined criteria for efficacy.
patients with AIDS-associated Kaposi sarcoma (KS). Treatment was associated with low
toxicity, but the KS clinical response and KS herpesvirus lytic induction rates were not
sufficiently high to meet predefined criteria for efficacy.
Abstract
The AIDS Malignancy Consortium undertook a pilot trial of valproic acid among patients with AIDS-associated Kaposi sarcoma (KS). Treatment was associated with low toxicity, but the KS clinical response and KS herpesvirus lytic induction rates were not sufficiently high to meet predefined criteria for efficacy.
Oxford University Press